Abstract
This manuscript describes the discovery and characterization of inhibitors of the lipid phosphatase SHIP2, an important target for the treatment of Type 2 diabetes, using the Automated Ligand Identification System. ALIS is an affinity selection-mass spectrometry platform for label-free, high throughput screening of mixture-based combinatorial libraries. We detail the mass-encoded synthesis of a library that yielded NGD-61338, a pyrazole-based SHIP2 inhibitor. Quantitative ALIS affinity measurements and inhibition of SHIP2 enzymatic activity indicate that this compound has micromolar binding affinity and inhibitory activity for this target. This inhibitor, which does not contain a phosphatase “warhead,” binds the active site of SHIP2 as determined by ALIS-based competition experiments with the enzymes natural substrate, phosphatidylinositol 3,4,5-triphosphate (PIP3). Structure-activity relationships for NGD-61338 and two other ligand classes discovered by ALIS screening were explored using a combination of combinatorial library synthesis and ALIS-enabled affinity ranking in compound mixtures.
Keywords: Affinity selection, mass spectrometry, high throughput screening, label-free, SHIP2, ALIS
Combinatorial Chemistry & High Throughput Screening
Title: Inhibitors of the Lipid Phosphatase SHIP2 Discovered by High Throughput Affinity Selection-Mass Spectrometry Screening of Combinatorial Libraries
Volume: 12 Issue: 8
Author(s): D. Allen Annis, Cliff C. Cheng, Cheng-Chi Chuang, John D. McCarter, Huw M. Nash, Naim Nazef, Todd Rowe, Robert J.M. Kurzeja and Gerald W. Shipps Jr.
Affiliation:
Keywords: Affinity selection, mass spectrometry, high throughput screening, label-free, SHIP2, ALIS
Abstract: This manuscript describes the discovery and characterization of inhibitors of the lipid phosphatase SHIP2, an important target for the treatment of Type 2 diabetes, using the Automated Ligand Identification System. ALIS is an affinity selection-mass spectrometry platform for label-free, high throughput screening of mixture-based combinatorial libraries. We detail the mass-encoded synthesis of a library that yielded NGD-61338, a pyrazole-based SHIP2 inhibitor. Quantitative ALIS affinity measurements and inhibition of SHIP2 enzymatic activity indicate that this compound has micromolar binding affinity and inhibitory activity for this target. This inhibitor, which does not contain a phosphatase “warhead,” binds the active site of SHIP2 as determined by ALIS-based competition experiments with the enzymes natural substrate, phosphatidylinositol 3,4,5-triphosphate (PIP3). Structure-activity relationships for NGD-61338 and two other ligand classes discovered by ALIS screening were explored using a combination of combinatorial library synthesis and ALIS-enabled affinity ranking in compound mixtures.
Export Options
About this article
Cite this article as:
Annis Allen D., Cheng C. Cliff, Chuang Cheng-Chi, McCarter D. John, Nash M. Huw, Nazef Naim, Rowe Todd, Kurzeja J.M. Robert and Shipps Jr. W. Gerald, Inhibitors of the Lipid Phosphatase SHIP2 Discovered by High Throughput Affinity Selection-Mass Spectrometry Screening of Combinatorial Libraries, Combinatorial Chemistry & High Throughput Screening 2009; 12 (8) . https://dx.doi.org/10.2174/138620709789104870
DOI https://dx.doi.org/10.2174/138620709789104870 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design Left Ventricular Hypertrophy in ADPKD: Changing Demographics
Current Hypertension Reviews Nardilysin, A Basic Residues Specific Metallopeptidase That Mediates Cell Migration and Proliferation
Protein & Peptide Letters HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Signaling Mechanisms by which Geniposide Regulates Insulin- Degrading Enzyme Expression in Primary Cortical Neurons
CNS & Neurological Disorders - Drug Targets Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Role of Microfluidics in Blood-Brain Barrier Permeability Cell Culture Modeling: Relevance to CNS Disorders
CNS & Neurological Disorders - Drug Targets NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?
Current Topics in Medicinal Chemistry The Proteasome in Health and Disease
Current Pharmaceutical Design Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Chronic Stress Impacts on Olfactory System
CNS & Neurological Disorders - Drug Targets Amino Acids as Pharmaco-Nutrients for the Treatment of Type 2 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Advanced Capillary and Microchip Electrophoretic Techniques for Proteomics
Current Proteomics Lipid Matrix Nanoparticles: Pharmacokinetics and Biopharmaceutics
Current Nanoscience Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets